RALEIGH, North Carolina, USA & TEL AVIV, Israel – June 9, 2026
RedHill Biopharma has received a significant regulatory boost after the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to opaganib for the treatment of neuroblastoma, one of the most common and deadly childhood cancers. The designation adds to opaganib’s existing Orphan Drug Designation for neuroblastoma, strengthening the drug’s regulatory profile and potentially accelerating its path toward clinical development and future commercialization. The FDA’s Rare Pediatric Disease designation may make opaganib eligible for a Priority Review Voucher (PRV) upon approval, while the existing orphan designation offers potential benefits including market exclusivity, tax credits, fee waivers, and expedited regulatory interactions. The milestone underscores growing interest in innovative therapies for pediatric oncology and highlights the potential of opaganib as a novel treatment approach for children facing high-risk neuroblastoma, where survival outcomes remain challenging despite advances in treatment.
FDA Designation Strengthens Development Pathway for Opaganib
The Rare Pediatric Disease designation is intended to encourage the development of therapies targeting serious or life-threatening diseases affecting fewer than 200,000 individuals in the United States, most of whom are children. For RedHill, the designation provides important regulatory incentives that could support future development and commercialization efforts. Opaganib already holds FDA Orphan Drug Designation for neuroblastoma, and the addition of Rare Pediatric Disease status further enhances the program’s strategic value. If ultimately approved, the therapy may qualify for a Priority Review Voucher, a valuable regulatory asset that can significantly accelerate review timelines for future drug applications.
Company executives noted that the designation reflects increasing recognition of opaganib’s potential therapeutic value and the urgent need for new treatment options in pediatric oncology. Neuroblastoma remains one of the most difficult childhood cancers to treat, particularly in high-risk patients where recurrence rates remain high and long-term survival outcomes are limited.
Preclinical Data Highlight Potential in High-Risk Neuroblastoma
Advertisement
The FDA designation follows encouraging preclinical findings presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting, where researchers reported positive results evaluating opaganib as a potential add-on therapy in neuroblastoma models. The data demonstrated that opaganib may enhance the effects of chemotherapy while targeting critical biological pathways involved in tumor growth and survival. Researchers observed evidence suggesting the therapy may destabilize N-Myc, a key oncogenic driver frequently associated with aggressive neuroblastoma and poor clinical outcomes.
Through modulation of sphingolipid metabolism and increased ceramide production, opaganib appears capable of promoting programmed cancer cell death, potentially improving treatment responses. The findings have generated interest among pediatric oncology researchers because N-Myc remains one of the most important therapeutic targets in high-risk neuroblastoma. The company is continuing discussions with academic partners and pediatric cancer research organizations regarding future development opportunities and potential clinical studies.
Expanding Opportunities for a Broad-Acting Oncology Candidate
Opaganib is a first-in-class oral sphingosine kinase-2 (SPHK2) selective inhibitor designed to target multiple disease pathways simultaneously. Beyond neuroblastoma, the investigational therapy is being evaluated across a broad range of oncology, viral, inflammatory, metabolic, and obesity-related indications. The drug has already demonstrated an encouraging safety and tolerability profile in more than 470 participants across multiple clinical studies, providing a strong foundation for continued development. RedHill is also advancing additional oncology programs involving opaganib, including an ongoing Phase 2 study in metastatic castration-resistant prostate cancer in combination with Bayer’s darolutamide.
The company believes the therapy’s broad mechanism of action may provide opportunities across multiple difficult-to-treat diseases. With the global neuroblastoma market projected to reach approximately $3.5 billion by 2032, the latest FDA designation strengthens RedHill’s position in pediatric oncology while highlighting the growing role of targeted and mechanism-based therapies in addressing rare childhood cancers. As development progresses, opaganib could emerge as an important new treatment option for patients facing one of the most challenging pediatric malignancies.
Source: RedHill Biopharma press release
